Shots:
- The companies expanded their license agreement for the research and development of an additional gene therapy for a lysosomal storage disorder. Takeda has exercised its option to initiate a fourth program based on the results from three initial programs
- Following the Mar’2020 agreement, Codexis has created the novel enzyme sequences to advance gene therapies into pre-clinical development by utilizing its CodeEvolver protein engineering platform
- Takeda is responsible for the pre/ clinical development and commercialization of gene therapy products emerges from the collaboration
Click here to read full press release/ article | Ref: GlobeNewswire | Image: GeneOnline
The post Takeda Expands its License Agreement with Codexis to Discover Novel Gene Therapies for Fourth Rare Genetic Disorders first appeared on PharmaShots.
